People

Shoshana Derrow Krilow is publicly listed by AFTD as Board Member. Her professional biography includes Vizient public-policy and government-relations leadership, University of California federal health affairs, congressional health policy and financial-services experience.

Guzide Adhikari leads CMC operations and strategy at QurAlis, which she joined in2021. Her published biography describes global clinical supply and operational roles at Translate Bio and Takeda/Shire, industrial-engineering training at Dokuz Eylul University and graduate operations-research studies at Northeastern.

Kimberly Radford Henderson is publicly listed by AFTD as Board Member. Her published career includes Meta global content marketing, Johnson & Johnson and Unilever brand strategy. She studied at Wake Forest and Duke’s Fuqua School.

Kasper Roet, PhD, is a co-founder and CEO of QurAlis, developing precision therapies for ALS and related neurodegeneration. He also co-founded EnClear Therapies and trained in neurobiology at the Netherlands Institute for Neuroscience, VU Amsterdam and Harvard; his research combines patient-derived stem-cell models with therapeutic target discovery.

Joe Esposito is publicly listed by AFTD as Board Member. AFTD identifies him as a Jennison managing director and portfolio manager since2014, previously at Loomis Sayles and AXA. His education includes The College of New Jersey and Columbia MBA; he is a CFA charterholder.

Gail Andersen is publicly listed by AFTD as Board Member. She retired after a thirty-one-year Procter & Gamble career including innovation leadership. Her AFTD chairmanship during2016–2020 is historical.

Halima Amjad is publicly listed by AFTD as Board Member. She is a Johns Hopkins geriatrician and dementia-care researcher, with medical education at Drexel, residency at Yale and fellowship training at Johns Hopkins.

Kyle Birmingham is publicly listed by AFTD as Board Member at Large. He is a portfolio manager at Quorus with prior financial-technology and Vanguard investment-strategy experience.

Valerie L. Snow is publicly listed by AFTD as Board Recording Secretary. She is a nonprofit lawyer whose professional practice supports access to disability services and representation in guardianship matters.

Julie Kelly is publicly listed by AFTD as Board Treasurer. Her published background includes managing director and private-client adviser at Logan Capital since2009, with previous BNY Mellon, Summit and ANB work and Indiana Kelley business education.

Leonard Marquez is publicly listed by AFTD as Board Vice Chair. His professional biography identifies AAMC government relations and legislative advocacy leadership, with previous roles at Cleveland Clinic, MetroHealth and in congressional service. He studied at Xavier and American University.

Rita B. Choula is publicly listed by AFTD as Board Chair. AFTD identifies her as AARP senior director for caregiving, connecting policy and practice.

Elizabeth R. Young is publicly listed by AFTD as Executive Assistant/Board Liaison. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Ashlyn Stienstra is publicly listed by AFTD as Fundraising Coordinator. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Ann Schoonover is publicly listed by AFTD as HelpLine Specialist. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Wendy Rollins is publicly listed by AFTD as Events Coordinator. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Cameron Reid is publicly listed by AFTD as Development Writer. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Lauren Pelaia is publicly listed by AFTD as Advocacy Coordinator. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Eva Morrison is publicly listed by AFTD as Social Media Coordinator. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Mike Mooney is publicly listed by AFTD as Marketing Cloud Coordinator. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Michael Mignone is publicly listed by AFTD as Education Coordinator. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Evelyn Lewis is publicly listed by AFTD as Volunteer Engagement Coordinator. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Olivia Klenn is publicly listed by AFTD as Administrative Assistant, Support and Education. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Hannah Gruen is publicly listed by AFTD as Volunteer Engagement Coordinator. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Samantha Garner is publicly listed by AFTD as Research Coordinator. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Hailey Fleischmann is publicly listed by AFTD as HelpLine Advisor. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Alyssa Fikaris is publicly listed by AFTD as HelpLine Advisor. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Erin Ficca is publicly listed by AFTD as Support Services Specialist. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Jeni Cardosi is publicly listed by AFTD as Human Resources Specialist. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Hilary Boucher is publicly listed by AFTD as Support Services Coordinator. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Yue Zhang is publicly listed by AFTD as Senior Accountant. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Jeff Thompson is publicly listed by AFTD as Operations Manager. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Kate Still is publicly listed by AFTD as Research Outreach Manager. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Sandy Sosa is publicly listed by AFTD as Social Media Manager. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Omair Siddiqui is publicly listed by AFTD as Digital Marketing Manager. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Jillian Shellenberger is publicly listed by AFTD as Events Manager. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Matthew Sharp is publicly listed by AFTD as Federal Advocacy Manager. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Stephanie Quigley is publicly listed by AFTD as HelpLine Manager. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Michael Mullan is publicly listed by AFTD as Volunteer Services Manager. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Sarah Lopata is publicly listed by AFTD as Support Services Manager. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Kim Jenny is publicly listed by AFTD as Manager of Genetic Initiatives. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Elizabeth Graham is publicly listed by AFTD as Corporate and Foundation Relations Manager. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Amanda Gleixner is publicly listed by AFTD as Research Projects Manager. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Danielle Gershkoff is publicly listed by AFTD as Donor Engagement Manager. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Jeanne Cestone is publicly listed by AFTD as Healthcare Education Manager. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Jenny Catchings is publicly listed by AFTD as State Advocacy Manager. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Abby Addvensky is publicly listed by AFTD as Annual Giving Manager. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Peter Witzleb is publicly listed by AFTD as Director of IT. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Michelle Thompson is publicly listed by AFTD as Director of Finance. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

PJ Lepp is publicly listed by AFTD as Director of Marketing & Communications. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Amanda Knight is publicly listed by AFTD as Director of Development. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Esther Kane is publicly listed by AFTD as Support & Education Director. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Marsha Jackson is publicly listed by AFTD as Director of Fundraising Events. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Bridget Graham is publicly listed by AFTD as Director of Meetings & Conferences. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Shana Dodge is publicly listed by AFTD as Director of Research Engagement. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Meghan Buzby is publicly listed by AFTD as Director of Advocacy and Volunteer Engagement. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Cynthia Brown-Smith is publicly listed by AFTD as Director of Human Resources. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Nicole Bjorklund is publicly listed by AFTD as Director of Research & Grants. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Phillip Weichel is publicly listed by AFTD as Vice President of Advancement. He became vice president in January2024 after leadership work at the Leukemia & Lymphoma Society, Cystic Fibrosis Foundation, Crohn’s and Colitis Foundation and Arthritis Foundation. He holds a Boston University MSW.

Sharon S. Denny is publicly listed by AFTD as Vice President of Mission Services. She joined AFTD in September2008 and leads support, education and advocacy. She holds clinical psychology qualifications from West Chester and psychology training from Holy Cross.

Penny Dacks is publicly listed by AFTD as Chief Scientific Officer. She joined AFTD in September2020 after scientific-programme roles at the American Epilepsy Society and Alzheimer’s Drug Discovery Foundation. She earned a neuroscience PhD at Arizona and leads AFTD research strategy; its directory also identifies her as president of the FTD Disorders Registry.

Mitch Appleson is publicly listed by AFTD as Chief Operating Officer. A CPA with an accounting degree from Yeshiva University and MBA from Saint Joseph’s, he joined AFTD in March2022 after serving as CFO of Alliance Cancer Specialists. His earlier healthcare and research administration roles included Columbia, CHOP, Penn and Drexel.

Rachel Biblow is publicly listed by AFTD as Chief Executive Officer. She previously led the Outcomes Institute, worked on transformation at Press Ganey and ChenMed, and spent more than fifteen years at Children’s Hospital of Philadelphia.

Greta Neffling is publicly named by Business Finland as coordinator and coauthor of the September 2026 Generative AI campaign retrospective. The campaign ended in June 2026; her source-qualified affiliation is recorded without inventing a successor-program role, personal investment or broader employment history.

Timo Sorsa is a Business Finland Head of Program and former Generative AI campaign head. His September 2026 retrospective states that the campaign ran from May 2024 to June 2026. Earlier official work describes data-economy ecosystems and AI applications. The ended campaign is not represented as currently operating, and future program plans are not assumed to be launched.

Tarja Enala is the Business Finland program director who led Health 360 Finland and authored its September 29, 2026 retrospective. The program supported health-sector research, international collaboration and digital and AI applications. Her own retrospective states that Health 360 ended in June 2026. This historical program is not presented as currently active; the publication establishes her program-director affiliation but not a new successor-program appointment.

Sini Uuttu is the publicly named project-manager contact for climate-neutral economy and renewable energy; the issuer’s December 2025 announcement also names her as project director. The current own media directory establishes this functional affiliation. Visit Finland, Work in Finland, Invest in Finland and shared group services are qualified as programs or services; this listing does not independently establish legal employment by the Innovation Funding Agency. Appointment dates and additional career details are not disclosed by this source.

Ulf-Erik Widd is the publicly named expert contact for smart machines and shipping. The current own media directory establishes this functional affiliation. Visit Finland, Work in Finland, Invest in Finland and shared group services are qualified as programs or services; this listing does not independently establish legal employment by the Innovation Funding Agency. Appointment dates and additional career details are not disclosed by this source.

Joonas Halla is the publicly named Work in Finland business-development manager contact. The current own media directory establishes this functional affiliation. Visit Finland, Work in Finland, Invest in Finland and shared group services are qualified as programs or services; this listing does not independently establish legal employment by the Innovation Funding Agency. Appointment dates and additional career details are not disclosed by this source.

Heli Saari is the publicly named Visit Finland area-manager contact. The current own media directory establishes this functional affiliation. Visit Finland, Work in Finland, Invest in Finland and shared group services are qualified as programs or services; this listing does not independently establish legal employment by the Innovation Funding Agency. Appointment dates and additional career details are not disclosed by this source.

Karin Wikman is the publicly named expert contact for leading-company innovation projects, research and development and associated ecosystems. The current own media directory establishes this functional affiliation. Visit Finland, Work in Finland, Invest in Finland and shared group services are qualified as programs or services; this listing does not independently establish legal employment by the Innovation Funding Agency. Appointment dates and additional career details are not disclosed by this source.

Susanna Lehto is the publicly named marketing coordinator and named contact for Business Finland media assets; own issuer portrait credits also identify her as photographer. The current own media directory establishes this functional affiliation. Visit Finland, Work in Finland, Invest in Finland and shared group services are qualified as programs or services; this listing does not independently establish legal employment by the Innovation Funding Agency. Appointment dates and additional career details are not disclosed by this source.

Salla Salovaara is the publicly named Business Finland and Invest in Finland communications contact; the Finnish current media page specifies International PR and Media, while the English media page uses a broader communications title. The current own media directory establishes this functional affiliation. Visit Finland, Work in Finland, Invest in Finland and shared group services are qualified as programs or services; this listing does not independently establish legal employment by the Innovation Funding Agency. Appointment dates and additional career details are not disclosed by this source.

Heli Hemgård is the publicly named shared Business Finland, Visit Finland and Work in Finland communications contact. The current own media directory establishes this functional affiliation. Visit Finland, Work in Finland, Invest in Finland and shared group services are qualified as programs or services; this listing does not independently establish legal employment by the Innovation Funding Agency. Appointment dates and additional career details are not disclosed by this source.

Maria Arruda is the publicly named Business Finland communications contact. The current own media directory establishes this functional affiliation. Visit Finland, Work in Finland, Invest in Finland and shared group services are qualified as programs or services; this listing does not independently establish legal employment by the Innovation Funding Agency. Appointment dates and additional career details are not disclosed by this source.

Maria Wasastjerna is member of Business Finland’s Governance Board for the appointed term March 23, 2026 to March 22, 2028. The current agency directory identifies the external affiliation as CEO of Kvanted in Business Finland’s directory and Managing Partner in Kvanted’s current own directory. The board governs the agency and the Business Finland group and makes funding decisions within government budget authorizations. Board affiliation is not a personal financial participation. Kvanted’s current primary biography identifies her as Managing Partner, with over 15 years of business-law experience in technology, mergers and acquisitions and digital markets. Her PhD concerned the data economy, and her investment focus includes industrial digital and data-driven innovation.

Outi Vaarala is member of Business Finland’s Governance Board for the appointed term March 23, 2026 to March 22, 2028. The current agency directory identifies the external affiliation as Executive Vice President at Orion. The board governs the agency and the Business Finland group and makes funding decisions within government budget authorizations. Board affiliation is not a personal financial participation. Orion’s current profile identifies her as Executive Vice President, Research & Development, with earlier oncology and translational-research leadership at Orion, AstraZeneca and MedImmune. She is a professor in pediatric immunology and autoimmune diseases and holds a medical doctorate. Orion independently confirms her Business Finland board membership from 2026.

Sean Salji was introduced by Citadel as Head of Surveyor Capital in Europe in its April 24, 2019 Citadel Conversations interview. He discussed developing investment teams and the resources available within the business. This is an explicitly historical published affiliation; a current Surveyor appointment, subsequent transition date and individual portrait are not established by that source.

Jarno Syrjälä is member of Business Finland’s Governance Board for the appointed term March 23, 2026 to March 22, 2028. The current agency directory identifies the external affiliation as Under-Secretary of State at the Ministry for Foreign Affairs. The board governs the agency and the Business Finland group and makes funding decisions within government budget authorizations. Board affiliation is not a personal financial participation.

Justin Lubell currently leads Citadel Global Equities, according to Citadel’s current leadership biography. The same biography records that he joined Citadel in 2020 as a senior managing director at Surveyor Capital and subsequently moved to lead the other equities unit. His Surveyor role is historical. Previously he spent more than a decade as a portfolio manager at Point72, worked in equity derivatives strategy at Bear Stearns and studied economics and political science at the University of Pennsylvania.

Juuso Heinilä is member of Business Finland’s Governance Board for the appointed term March 23, 2026 to March 22, 2028. The current agency directory identifies the external affiliation as CEO of Finnvera. The board governs the agency and the Business Finland group and makes funding decisions within government budget authorizations. Board affiliation is not a personal financial participation. Finnvera’s official appointment announcement identifies him as CEO from June 1, 2024, following responsibility for its SME financing.

Yi Zhou is named a Surveyor Capital healthcare portfolio manager in the 2022 leading women in hedge funds profile republished by Citadel. The published biography describes a background in healthcare investing and research, earlier work at JPMorgan and SAC, and economics and mathematics studies at MIT. Her Surveyor affiliation is recorded as published in 2022; a subsequent current role and exact transition dates are not independently verified.

Paula Eerola is member of Business Finland’s Governance Board for the appointed term March 23, 2026 to March 22, 2028. The current agency directory identifies the external affiliation as Director General of the Research Council of Finland. The board governs the agency and the Business Finland group and makes funding decisions within government budget authorizations. Board affiliation is not a personal financial participation. The Research Council of Finland’s own leadership directory independently identifies her as Director General responsible for the agency’s administration.

Micah Nance is profiled as a Surveyor Capital technology and media portfolio manager and Citadel partner in a January 2025 interview published as an authorized reprint on Citadel’s website. The profile reports that he joined Citadel in 2012 and became a partner in 2023, working with a Dallas team. Before Citadel he worked in Morgan Stanley equity research and studied at Texas A&M. His role is qualified to the publication date rather than an independently verified October 2026 appointment.

Tiina Korhonen is vice chair of Business Finland’s Governance Board for the appointed term March 23, 2026 to March 22, 2028. The current agency directory identifies the external affiliation as Head of Department at the Ministry of Economic Affairs and Employment. The board governs the agency and the Business Finland group and makes funding decisions within government budget authorizations. Board affiliation is not a personal financial participation.

Mackenzie Snyder is named Head of Business Development at Surveyor Capital in Citadel’s own 2026 congratulatory post, preserved as an embedded company post in a public repost. The award organizer independently identifies her Surveyor Capital, Citadel affiliation among its 2026 hedge fund rising stars. Her own LinkedIn identifies Citadel and Williams College. The exact appointment day and an authentic individually named portrait have not been verified.

Phillip Lee leads Surveyor Capital, a Citadel fundamental equities unit, and serves on Citadel’s Portfolio Committee. Citadel’s current biography says he joined Surveyor in 2013 as a senior TMT analyst, became a portfolio manager in 2015 and later served as U.S. deputy head and senior mentor before becoming head in 2021. Previously he worked in Morgan Stanley technology investment banking and at Cadian Capital. He holds an economics BA from Dartmouth and an MBA from Stanford.

Teppo Rantanen is chair of Business Finland’s Governance Board for the appointed term March 23, 2026 to March 22, 2028. The current agency directory identifies the external affiliation as Executive Director at the City of Tampere. The board governs the agency and the Business Finland group and makes funding decisions within government budget authorizations. Board affiliation is not a personal financial participation.

Teija Lahti-Nuuttila leads the Director General’s Office at Business Finland. Earlier event materials describe customer and network responsibilities, while the current leadership directory identifies the Director General’s Office role. This is the publicly listed Business Finland group leadership affiliation. The grant agency and Business Finland Oy are legally separate; a current individual legal employment contract is not established by the shared directory. No personal investment is inferred.

Heidi Elvilä leads talent, legal and administration at Business Finland. Agency documents identify her historic agency personnel responsibilities; the current organization directory publishes the broader shared leadership role. This is the publicly listed Business Finland group leadership affiliation. The grant agency and Business Finland Oy are legally separate; a current individual legal employment contract is not established by the shared directory. No personal investment is inferred.

Hannu Kemppainen leads insight and finance at Business Finland. His earlier published work as strategy director concerns innovation-driven growth and export competitiveness; that earlier title is not substituted for the current leadership directory. This is the publicly listed Business Finland group leadership affiliation. The grant agency and Business Finland Oy are legally separate; a current individual legal employment contract is not established by the shared directory. No personal investment is inferred.

Jenni Santalo leads marketing, communications and digital solutions at Business Finland. She joined its leadership in May 2024 after serving as VTT’s marketing and communications director; the agency’s appointment announcement describes experience in marketing, digital growth and customer experience. This is the publicly listed Business Finland group leadership affiliation. The grant agency and Business Finland Oy are legally separate; a current individual legal employment contract is not established by the shared directory. No personal investment is inferred.

Risto Vuohelainen leads the growth-services area of Business Finland. His published work discusses innovation, commercialization and international growth. His prior internationalization-services title is historical. This is the publicly listed Business Finland group leadership affiliation. The grant agency and Business Finland Oy are legally separate; a current individual legal employment contract is not established by the shared directory. No personal investment is inferred.

Timo Metsä-Tokila leads Business Finland’s funding services. His current public commentary concerns research and development funding and the application and funding-decision process. This is the publicly listed Business Finland group leadership affiliation. The grant agency and Business Finland Oy are legally separate; a current individual legal employment contract is not established by the shared directory. No personal investment is inferred.

Lassi Noponen is Director General of the Innovation Funding Agency Business Finland. The Finnish Government appointed him for a five-year term beginning September 1, 2024. His current responsibilities include leading the public innovation funding and growth organization. The official appointment describes qualifications in law and a Master of Science. His role concerns institutional funding decisions and policy execution, not personal investments.

Published co-founder of Clarified Precision Medicine; current operating role is unverified.

Chief Executive Officer at Clarified Precision Medicine, which combines machine-learning analysis with medical expert review for personalized oncology treatment guidance.

Board Member at Clarified Precision Medicine, which combines machine-learning analysis with medical expert review for personalized oncology treatment guidance.

Chief Technology Officer at Clarified Precision Medicine, which combines machine-learning analysis with medical expert review for personalized oncology treatment guidance.

Co-founder of Clarified Precision Medicine, published as Scientific Advisor in its April2024 financing announcement; own current directory retains the cofounder affiliation.

Co-Founder at Clarified Precision Medicine, which combines machine-learning analysis with medical expert review for personalized oncology treatment guidance.

Co-Founder and Medical Director at Clarified Precision Medicine, which combines machine-learning analysis with medical expert review for personalized oncology treatment guidance.

Jeff Albers is listed by Atlas Venture as venture partner. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Linda C. Bain is listed by Atlas Venture as venture partner. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Josh Powers is listed by Atlas Venture as finance manager. Published educational qualifications include BS, magna cum laude, Endicott College. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Jernej Godec is listed by Atlas Venture as venture partner. The same directory identifies an outside portfolio role: Chief Executive Officer, Stealth NewCo. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Pascal Fortin is listed by Atlas Venture as entrepreneur-in-residence. The same directory identifies an outside portfolio role: President and Chief Scientific Officer, Stealth NewCo. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Ram Aiyar is listed by Atlas Venture as atlas advisor. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Sean Burns is listed by Atlas Venture as entrepreneur-in-residence. The same directory identifies an outside portfolio role: Chief Scientific Officer, Stealth NewCo. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Andre Turenne is listed by Atlas Venture as atlas advisor. The same directory identifies an outside portfolio role: Chief Executive Officer, Matchpoint Therapeutics. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Alex Harding is listed by Atlas Venture as entrepreneur-in-residence. The same directory identifies an outside portfolio role: Chief Executive Officer, Stealth NewCo. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Michael Gladstone is listed by Atlas Venture as partner. Published educational qualifications include AB, magna cum laude, Harvard College. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Lainey Rabinow is listed by Atlas Venture as executive assistant. Published educational qualifications include BA, University of Massachusetts Amherst. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

John Quisel is listed by Atlas Venture as atlas advisor. The same directory identifies an outside portfolio role: President & Chief Executive Officer, Disc Medicine. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Nick Keen is listed by Atlas Venture as entrepreneur-in-residence. The same directory identifies an outside portfolio role: Founder & Chief Scientific Officer, Stealth NewCo. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Angela Lam is listed by Atlas Venture as executive assistant. Published educational qualifications include BA, University of New Hampshire. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Essra Ridha is listed by Atlas Venture as entrepreneur-in-residence. The same directory identifies an outside portfolio role: President and Chief Medical Officer, Spolia Therapeutics. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Steven Sweeney is listed by Atlas Venture as entrepreneur-in-residence. The same directory identifies an outside portfolio role: Chief Executive Officer, Stealth NewCo. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Andrea DiMella is listed by Atlas Venture as senior vice president, head of talent. Published educational qualifications include BA, University of California at Santa Cruz. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Kyle Shuckerow is listed by Atlas Venture as finance manager. Published educational qualifications include BS, University of Connecticut. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Ommer Chohan is listed by Atlas Venture as chief financial officer. Published educational qualifications include Master of Legal Studies, Washington University in St. Louis MBA, Johnson School at Cornell University BA, University of Toronto. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Investor, former CEO of RENK Group AG; Supervisory Board member at Volkswagen AG, Brenntag SE and BWI GmbH

CEO of CX2, serial entrepreneur in autonomous systems

Principal AI Architect in the Office of the CTO, at Microsoft. Turning frontier AI into a compounding innovation engine

CEO of Hut 8 Corp. (NASDAQ, TSX: HUT)

Co-founder & Chief Product Officer, SolarEdge Technologies

Former CEO of Tesla Israel, Israeli Navy Naval Academy graduate and combat officer, seasoned technology leader and entrepreneur

Cleveland Clinic CIO & Neurology Professor; Executive Lead (Discovery Accelerator) in Quantum computing and AI

Physics professor at the Weizmann Institute of Science, expert in quantum computing and quantum optics

Yarden Golan is a Deep33 venture partner and former Chief of Staff to Israel’s Minister of Strategic Affairs and to the Israeli Ambassador to the United States.

Lior Prosor is a Deep33 partner with more than a decade of venture capital investment experience.

Strategy and ecosystem leader with 10+ years across innovation and deep tech; Ex-Deloitte Catalyst, 8200 Alumni Association, critical minerals thought leader

Michael Broukhim is a Deep33 partner and FabFitFun co-founder and co-CEO.

Investor with 6+ years of VC and M&A experience across Israel and the U.S.; Ex-Arkin, EY, Ceragon, ServiceNow

Former Commander of Israel’s elite Talpiot Program (ret.Col); MSc in Quantum Optics; Global Quantum Ecosystem Advisor

Investor with 10+ years across AI, product, and deep tech; Ex-8200 Major, AI & Infra lead at Hetz Ventures and Zebra Medical

Mark Tebbe is listed by Atlas Venture as entrepreneur-in-residence. The same directory identifies an outside portfolio role: Chief Technology Officer, Spolia Therapeutics. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Judith Dunn is listed by Atlas Venture as atlas advisor. The same directory identifies an outside portfolio role: President and Head of R&D, Vima Therapeutics. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Samantha Singer is listed by Atlas Venture as entrepreneur in residence. The same directory identifies an outside portfolio role: Chief Executive Officer and President, Stealth NewCo. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Scott Ribich is listed by Atlas Venture as entrepreneur-in-residence. The same directory identifies an outside portfolio role: Chief Scientific Officer, Stealth NewCo. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Owen Hughes is listed by Atlas Venture as entrepreneur-in-residence. The same directory identifies an outside portfolio role: Chief Executive Officer, Stealth NewCo. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Robert Hughes, also published as Rob Hughes, is an Atlas adviser and EVP of drug discovery and preclinical development at Rectify Pharmaceuticals. His biography describes earlier molecular-discovery leadership at Disarm and research positions at Boehringer Ingelheim and Pfizer, including neurodegeneration. He earned a Scripps chemistry PhD and an Arizona chemistry/mathematics degree. He is distinct from the STRM.BIO finance executive with the same name.

Andy Mulvaney is listed by Vesper Bio as External Business Development Consultant. Biotechnology business-development executive who co-founded VASTox/Summit and later served as OxStem COO. Holds a Cardiff organometallic-chemistry doctorate and worked in Oxford postdoctoral chemistry research.

Sarah Gerrish is listed by Atlas Venture as executive assistant. Published educational qualifications include BS, cum laude, Plymouth State University. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Jean-François Formela is listed by Atlas Venture as partner. Published educational qualifications include MD, Paris University School of Medicine MBA, Columbia University. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment. Bruce Booth’s December5,2024 fund announcement states that Formela remains a partner overseeing his existing portfolio but will not make new Fund XIV investments.

Jared Cumming is listed by Atlas Venture as atlas advisor. The same directory identifies an outside portfolio role: Chief Scientific Officer, Matchpoint Therapeutics. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Nello Mainolfi is listed by Atlas Venture as atlas advisor. The same directory identifies an outside portfolio role: Chief Executive Officer and President, Kymera Therapeutics. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Dania Rabah is listed by Atlas Venture as entrepreneur-in-residence. The same directory identifies an outside portfolio role: Co-Founder and Chief Scientific Officer, Stealth NewCo. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Niranjan Kameswaran is listed by Atlas Venture as atlas advisor. The same directory identifies an outside portfolio role: Chief Executive Officer, Ethyreal Bio. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Stella Paffenholz is listed by Atlas Venture as senior associate. Published educational qualifications include PhD, Gerstner Sloan Kettering Graduate School of Biomedical Sciences MS, German Cancer Research Center / University of Heidelberg BS, University of Bonn. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Kristen Margeson is listed by Atlas Venture as vice president of investor relations and marketing. Published educational qualifications include BS, magna cum laude, Simmons College. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Aimee Raleigh is listed by Atlas Venture as principal. Published educational qualifications include PhD, University of California, San Diego BSE, Duke University. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Rubina Parmar is listed by Atlas Venture as atlas advisor. The same directory identifies an outside portfolio role: Head of Technology, Stealth NewCo. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Peter Barrett is an Atlas partner for legacy funds, with therapeutic-company creation work at Atlas since 2002. He previously co-founded Celera Genomics and held executive and business-development responsibilities there. His own Atlas biography identifies biotechnology board positions and past therapeutic-company investments. He is distinct from Playground Global’s founder Peter Barrett; the two identities and affiliations are preserved separately.

Wenlin Shao is listed by Atlas Venture as entrepreneur-in-residence. The same directory identifies an outside portfolio role: Chief Development Officer, Stealth NewCo. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

John King-Underwood is listed by Vesper Bio as External Medicinal Chemistry Consultant. Computational-chemistry consultant working with medicinal chemistry, molecular modelling, structure-based design, virtual screening and informatics; own XPose directory confirms the same named computational-chemistry adviser.

Graham Wynne is listed by Vesper Bio as External Medicinal Chemistry Consultant. Founder of930 Consulting, advising medicinal-chemistry and drug-discovery projects. Holds a Nottingham organic-chemistry doctorate and undertook postdoctoral research at the Australian National University.

Jørgen Erik Nielsen is listed by Vesper Bio as Scientific Advisor. University of Copenhagen clinical professor in neurology based at Rigshospitalet. This clinician is distinct from the deceased literary scholar of the same name; detailed education is not stated by the current official directory.

James B. Rowe is listed by Vesper Bio as Scientific Advisor. Cambridge cognitive-neurology professor studying Alzheimer’s disease, frontotemporal dementia and related disorders. Trained at Cambridge, Oxford and UCL, followed by specialist neurology training in London/Copenhagen; directs Cambridge’s FTD centre.

Caroline Breitbach is listed by Atlas Venture as entrepreneur-in-residence. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Akshay Vaishnaw is listed by Atlas Venture as venture partner. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Evan Thackaberry is listed by Atlas Venture as entrepreneur-in-residence. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Geraldine Harriman is listed by Atlas Venture as atlas advisor. The same directory identifies an outside portfolio role: Co-Founder and Chief Scientific Officer, HotSpot Therapeutics. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Jeff Trigilio is listed by Atlas Venture as entrepreneur-in-residence. The same directory identifies an outside portfolio role: Chief Financial and Chief Business Officer, Stealth NewCo. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

John Cox is listed by Atlas Venture as atlas advisor. The same directory identifies an outside portfolio role: President and Chief Executive Officer, Dyne Therapeutics. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Vito Palombella is listed by Atlas Venture as atlas advisor. The same directory identifies an outside portfolio role: Chief Scientific Officer, TRIANA Biomedicines. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Maurizio Fazio is listed by Atlas Venture as principal. Published educational qualifications include PhD, Harvard University MD, cum laude with honor mention, Vita-Salute San Raffaele University. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Rajesh Devraj is listed by Atlas Venture as venture partner. The same directory identifies an outside portfolio role: President & Chief Executive Officer, Rectify Pharmaceuticals. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Katharine Unangst is listed by Atlas Venture as executive assistant. Published educational qualifications include Palm Beach State College. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

David Grayzel is listed by Atlas Venture as partner. Published educational qualifications include MD, Harvard Medical School BA with honors, Stanford University. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Praveen Tipirneni is listed by Atlas Venture as venture partner. The same directory identifies an outside portfolio role: Chief Executive Officer, Caldera Therapeutics. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Eben Tessari is listed by Atlas Venture as entrepreneur-in-residence. The same directory identifies an outside portfolio role: Chief Executive Officer, Calixis. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Eric Schmid is listed by Atlas Venture as vice president, legal affairs. Published educational qualifications include JD, magna cum laude, Boston College Law School BA, Wake Forest University. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Steven Robinette is listed by Atlas Venture as venture partner. The same directory identifies an outside portfolio role: Chief Executive Officer, Spolia Therapeutics. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Shelia Violette is listed by Atlas Venture as atlas advisor. The same directory identifies an outside portfolio role: Founder, Chief Scientific Officer, President of Research, Q32 Bio. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Justin Feng is listed by Atlas Venture as senior associate. Published educational qualifications include PhD, Harvard University BS with High Honors, University of California, Berkeley. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Eric J. Huang is listed by Vesper Bio as Scientific Advisor. WashU pathology/immunology chair and neuropathologist studying neural development and neurodegeneration. MD from National Taiwan University, Cornell/Sloan-Kettering doctorate and UCSF neuropathology/postdoctoral training. This is distinct from Delos investor Eric Huang.

Jonathan Rohrer is listed by Vesper Bio as Scientific Advisor. UCL-associated neurologist researching young-onset and genetic dementias. Studied natural sciences at Cambridge and medicine at Oxford/UCL, with specialist neurology training in London.

Steve Finkbeiner is listed by Vesper Bio as Scientific Advisor. UCSF neurology professor researching neuronal plasticity, memory and neurodegeneration, including Huntington’s disease. Trained in medicine/neuroscience at Yale and neurology at UCSF.

Mike Forkel is listed by Atlas Venture as vice president, finance. Published educational qualifications include MBA, Boston College Carroll School of Management BA, College of the Holy Cross. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Kevin Bitterman is listed by Atlas Venture as partner. Published educational qualifications include PhD, Harvard Medical School BA with highest honors, Rutgers University. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Phillip Samayoa is listed by Atlas Venture as venture partner. The same directory identifies an outside portfolio role: Chief Operating Officer, Ethyreal Bio. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Kathy Doherty is listed by Atlas Venture as receptionist. Published educational qualifications include Charlestown High School. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Bob Copeland is listed by Atlas Venture as venture partner. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Constantine Chinoporos is listed by Atlas Venture as atlas advisor. The same directory identifies an outside portfolio role: Executive Chairman, Rectify Pharmaceuticals. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Julia Pian is listed by Atlas Venture as senior associate. Published educational qualifications include MD, Harvard Medical School MBA, Harvard Business School AB, summa cum laude, Harvard College. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Vishal Patel is listed by Atlas Venture as atlas advisor. The same directory identifies an outside portfolio role: Chief Executive Officer, Triveni Bio. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Laura Alessio is listed by Atlas Venture as director of portfolio operations. Published educational qualifications include BSBA, Middlesex College. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Eleanor Ronan is listed by Atlas Venture as manager of talent and hr operations. Published educational qualifications include BS, University of Richmond. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Peter Smith, also published as Pete Smith, is co-founder, president and CEO of Remix Therapeutics and an Atlas adviser. His biography describes earlier scientific leadership at H3 Biomedicine and oncology drug discovery at Takeda and Millennium. He completed a Newcastle University PhD and postdoctoral research at Dana-Farber. He is distinct from the EQT infrastructure investor with the same name.

Diana Brainard is listed by Atlas Venture as entrepreneur-in-residence. The same directory identifies an outside portfolio role: Chief Executive Officer, Stealth NewCo. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Jason Rhodes is listed by Atlas Venture as partner. Published educational qualifications include MBA, Wharton BA, Yale University. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Natalia Misciattelli is listed by Atlas Venture as atlas advisor. The same directory identifies an outside portfolio role: Chief Executive Officer, AAVantgarde Bio. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Jonathan Montagu is listed by Atlas Venture as atlas advisor. The same directory identifies an outside portfolio role: Chief Executive Officer, HotSpot Therapeutics. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Diana Francis is listed by Atlas Venture as controller. Published educational qualifications include MST, Bentley University BS, magna cum laude, Bentley University. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Meaghan Gallagher is listed by Atlas Venture as executive assistant. Published educational qualifications include BA, Assumption College. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Alex Lugovskoy is listed by Atlas Venture as atlas advisor. The same directory identifies an outside portfolio role: Chief Executive Officer, Diagonal Therapeutics. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Brenton Mar is listed by Atlas Venture as entrepreneur-in-residence. The same directory identifies an outside portfolio role: Chief Medical Officer, Stealth NewCo. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Douglas Kerr is listed by Atlas Venture as atlas advisor. The same directory identifies an outside portfolio role: Chief Medical Officer, Dyne Therapeutics. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Timothy P. Reilly is listed by Atlas Venture as entrepreneur-in-residence. The same directory identifies an outside portfolio role: Head of R&D, Stealth NewCo. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Farah Lewis is listed by Atlas Venture as executive assistant. Published educational qualifications include BA, Tufts University B.Mus, New England Conservatory. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Alfica Sehgal is listed by Atlas Venture as entrepreneur-in-residence. The same directory identifies an outside portfolio role: Chief Scientific Officer, Judo Bio. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Simon Read is listed by Atlas Venture as venture partner. The same directory identifies an outside portfolio role: Acting Chief Executive Officer, Judo Bio. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Haojing Rong is listed by Atlas Venture as entrepreneur-in-residence. The same directory identifies an outside portfolio role: Chief Development Officer, Spolia Therapeutics. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Olivier Heckmann is identified in Anaxago’s public group governance directory as Administrateur. The record uses the official named portrait adjacent to this person’s card. This is the published group affiliation; exact legal employing subsidiary and any later changes are not assumed. Anaxago Capital roles on the legacy directory are qualified by the December2025 Ambra rebrand.

Arnaud Giraudon is identified in Anaxago’s public group governance directory as Administrateur. The record uses the official named portrait adjacent to this person’s card. This is the published group affiliation; exact legal employing subsidiary and any later changes are not assumed. Anaxago Capital roles on the legacy directory are qualified by the December2025 Ambra rebrand.

Patrice Hutin is identified in Anaxago’s public group governance directory as Administrateur. The record uses the official named portrait adjacent to this person’s card. This is the published group affiliation; exact legal employing subsidiary and any later changes are not assumed. Anaxago Capital roles on the legacy directory are qualified by the December2025 Ambra rebrand.

Guillaume Regert is identified in Anaxago’s public group governance directory as Directeur de l'Investissement et de l'Asset Management. The record uses the official named portrait adjacent to this person’s card. This is the published group affiliation; exact legal employing subsidiary and any later changes are not assumed. Anaxago Capital roles on the legacy directory are qualified by the December2025 Ambra rebrand. Guillaume Regert is published as Director of Investment and Real Estate Asset Management by Ambra Capital. The caption supports the stated institutional responsibility; no unverified educational history, exact tenure day or individual investment is inferred.

Bruno Blanc is identified in Anaxago’s public group governance directory as Directeur Général Adjoint. The record uses the official named portrait adjacent to this person’s card. This is the published group affiliation; exact legal employing subsidiary and any later changes are not assumed. Anaxago Capital roles on the legacy directory are qualified by the December2025 Ambra rebrand. Bruno Blanc is published as Deputy Managing Director by Ambra Capital. The caption supports the stated institutional responsibility; no unverified educational history, exact tenure day or individual investment is inferred.

Chloë Brun is identified in Anaxago’s public group governance directory as Présidente d'Anaxago et d'Anaxago Patrimony. The record uses the official named portrait adjacent to this person’s card. This is the published group affiliation; exact legal employing subsidiary and any later changes are not assumed. Anaxago Capital roles on the legacy directory are qualified by the December2025 Ambra rebrand.

Guillaume Dupont is identified in Anaxago’s public group governance directory as Directeur Général Anaxago Capital. The record uses the official named portrait adjacent to this person’s card. This is the published group affiliation; exact legal employing subsidiary and any later changes are not assumed. Anaxago Capital roles on the legacy directory are qualified by the December2025 Ambra rebrand. Guillaume Dupont is published as Venture Partner — CapHorn venture brand by the CapHorn venture-capital brand. The own biography identifies him as founder of CapHorn in2011 and describes over20 years in venture capital; the heading currently says Venture Partner while older body text says Managing Partner.

Joachim Dupont is identified in Anaxago’s public group governance directory as Président Anaxago Capital. The record uses the official named portrait adjacent to this person’s card. This is the published group affiliation; exact legal employing subsidiary and any later changes are not assumed. Anaxago Capital roles on the legacy directory are qualified by the December2025 Ambra rebrand. Joachim Dupont is published as President by Ambra Capital. The caption supports the stated institutional responsibility; no unverified educational history, exact tenure day or individual investment is inferred.

Caroline Lamaud is identified in Anaxago’s public group governance directory as Présidente Conseil d'Administration. The record uses the official named portrait adjacent to this person’s card. This is the published group affiliation; exact legal employing subsidiary and any later changes are not assumed. Anaxago Capital roles on the legacy directory are qualified by the December2025 Ambra rebrand.

Anna Ravnefjord is currently listed by Vesper Bio as REGULATORY AFFAIRS SPECIALIST. Works in regulatory affairs for investigational drug development; current role is source-qualified without invented education.

Tina Vig is currently listed by Vesper Bio as SENIOR CLINICAL TRIAL MANAGER. Manages clinical trials of the company’s investigational neuroscience programmes; no full appointment date is disclosed.

Brittany Lo Cicero is currently listed by Vesper Bio as EXECUTIVE ASSISTANT AND OFFICE MANAGER. Supports leadership, office operations and internal communications.

Anders Riisager is currently listed by Vesper Bio as SENIOR PROJECT MANAGER. Coordinates Vesper scientific-development projects; no unverified academic qualification or historical start date is inferred.

Lærke Fensbæk is currently listed by Vesper Bio as ASSOCIATE CLINICAL TRIAL MANAGER . Coordinates clinical trials at the Copenhagen investigational CNS-drug developer; detailed academic credentials are not asserted.

Imogen Swift is currently listed by Vesper Bio as SENIOR RESEARCH SCIENTIST. Works on neuroscience research and clinical-development programmes; academic history is not established by the current employer profile.

Mads Kjølby is currently listed by Vesper Bio as FOUNDER & CMO. Cofounder and chief medical officer overseeing clinical development, with more than a decade of clinical-pharmacology experience and specialist sortilin research.

Louise Klem is currently listed by Vesper Bio as LEAD RESEARCH SCIENTIST. Investigates sortilin inhibition and progranulin in neurodegeneration; issuer identifies her as principal investigator of its2024 MJFF Parkinson’s grant.

Lovisa Sunesson is currently listed by Vesper Bio as DIRECTOR OF BUSINESS DEVELOPMENT. Works across fundraising, partnering and company promotion in neuroscience-focused biotechnology.

Ivana Henckel von Donnersmarck is currently listed on Skybound Venture Capital’s published team as VP (published acronym; expansion unconfirmed). The firm backs pre-seed and seed-stage deep-technology companies.

Natalie Dayan is currently listed on Skybound Venture Capital’s published team as Associate. The firm backs pre-seed and seed-stage deep-technology companies.

Thaleia Misailidou is currently listed on Skybound Venture Capital’s published team as General Partner. The firm backs pre-seed and seed-stage deep-technology companies.

George Varvarelis is currently listed on Skybound Venture Capital’s published team as General Partner. The firm backs pre-seed and seed-stage deep-technology companies.

Nina Schultz is currently listed by Vesper Bio as PRINCIPAL RESEARCH SCIENTIST. Works on Vesper’s preclinical neurodegeneration and sortilin-inhibition research; detailed education is not published in the current company biography.

Ove Pedersen is currently listed by Vesper Bio as SVP OF CMC & PRECLINICAL DEVELOPMENT. Oversees clinical-trial medicine development/manufacturing, active-ingredient safety testing and quality assurance; previously served Vesper as chemistry/manufacturing consultant.

Sofie Let Frandsen is currently listed by Vesper Bio as SENIOR RESEARCH SCIENTIST. Designs and coordinates preclinical in-vivo and in-vitro neurodegeneration studies investigating sortilin inhibition.

Masashi Oka is listed by Geodesic Capital as Senior Advisor. Advises Geodesic after financial and technology leadership at MUFG, Nikon and Sony Financial Group.

Kurt Tong is listed by Geodesic Capital as Senior Advisor. Advises Geodesic while serving as The Asia Group managing partner; previously a U.S. diplomat in Japan and Hong Kong.

James Kondo is listed by Geodesic Capital as Senior Advisor. Advises on technology, management and policy; chairs International House of Japan and previously led Twitter Japan.

Hyesu Sai is listed by Geodesic Capital as Manager of Events and Marketing (Geodesic Japan, G.K. group affiliation). Plans Japan events, produces the Geodesic Japan Newsletter and supports portfolio-company marketing; previously worked at JTB Communication Design.

Chick Runkel is listed by Geodesic Capital as Project Manager. Manages projects after a career in IBM sales, marketing and management.

Jessica Lazos is listed by Geodesic Capital as Executive Assistant. Supports founding partner John Roos and U.S. office administration after administrative and marketing work at Carr McClellan.

Stavroula Cannon is listed by Geodesic Capital as Administrative Assistant and Office Manager. Supports the U.S. office and previously managed executive assistance and facilities work in real estate and biotechnology.

Etsuko Aoyama is listed by Geodesic Capital as Manager of Events Marketing. Plans and runs Geodesic Forum and other events; previously led event programmes at JTB USA and JAPAN HOUSE Los Angeles.

Alvin Asper is listed by Geodesic Capital as Chief Financial Officer. Manages finance, reporting and audit after controller work at Kleiner Perkins and fund accounting at Mayfield.

Shiro Watanabe is listed by Geodesic Capital as Director, LP Digital Strategy (Geodesic Japan, G.K. group affiliation). Helps limited partners identify technology-business partners; previously worked on venture investments and cross-border M&A at Macnica.

Takayuki Otsuka is listed by Geodesic Capital as Director of Business Development (Geodesic Japan, G.K. group affiliation). Supports portfolio companies with Japanese go-to-market strategy after sales and product roles at Apple, Microsoft, Nokia and JVC.

Joshua Parker is listed by Geodesic Capital as Associate (Alliance Fund). Focuses on early-stage deep technology and energy resilience after Teneo consulting and technology investment banking.

Justin Yue is listed by Geodesic Capital as Senior Associate. Works on deal sourcing, execution and portfolio support after technology investment banking at Bank of America.

Will Horyn is listed by Geodesic Capital as Principal. Sources and executes enterprise-software investments; previously worked on Cisco acquisitions and venture investments.

Rayfe Gaspar-Asaoka is listed by Geodesic Capital as Partner (Alliance Fund). Invests in early-stage AI, space, cybersecurity and autonomy after serving as a Canaan partner.

Neb Mela is listed by Geodesic Capital as Partner. Nebiu (Neb) Mela invests in AI, advanced manufacturing, healthcare, energy and robotics after Tishman Speyer Ventures and Intel Capital.

Divya Sudhakar is listed by Geodesic Capital as Partner. Invests in enterprise software after investment roles at Intel Capital and In-Q-Tel.

Arvind Ayyala is listed by Geodesic Capital as Partner. Invests in enterprise software, fintech, healthcare and sustainable technology; previously worked at EDBI.

Brent Wu is listed by Geodesic Capital as Partner; Manages Investor Relations. Manages investor relations after leading business development at Kespry and Blackhawk Network.

Suzanne Basalla is listed by Geodesic Capital as Partner (Alliance Fund). Works on the Alliance Fund after leading the U.S.-Japan Council and serving as Toyota Research Institute chief of staff.

Marcus Otsuji is listed by Geodesic Capital as Country Manager (Geodesic Japan, G.K. group affiliation). Leads the Japanese portfolio-support operation; previously held country leadership and sales roles at Omniture and Apple Japan.

Susie Roos is listed by Geodesic Capital as Partner and Chief Administrative Officer. Previously an employment and labour attorney; helped found the TOMODACHI initiative.

Matt Fuller is listed by Geodesic Capital as Partner; Leads Investor Relations, Fundraising and International. Previously an American diplomat, including service on the White House National Security Council.

Jon Rezneck is listed by Geodesic Capital as Partner, Head of Investment Team and Chief Operating Officer. Covers fintech and previously worked in investment banking at Greenhill and JP Morgan.

John Roos is listed by Geodesic Capital as Founding Partner. Previously U.S. Ambassador to Japan and CEO of Wilson Sonsini Goodrich & Rosati. Current Salesforce primary-source qualification: John V. Roos is a Salesforce board director. Roos is Former U.S. Ambassador to Japan; Co-Founder, Geodesic Capital at Salesforce. He has served on Salesforce’s board since September 2013. He was US ambassador to Japan from 2009 to 2013 and later co-founded Geodesic Capital, focusing on growth-stage technology investing.

Director at RTX Ventures, the corporate venture capital arm of RTX.

Executive Director at RTX Ventures, the corporate venture capital arm of RTX.

Senior Director at RTX Ventures, the corporate venture capital arm of RTX.

Executive Assistant at RTX Ventures, the corporate venture capital arm of RTX.

Director at RTX Ventures, the corporate venture capital arm of RTX.

Executive Director at RTX Ventures, the corporate venture capital arm of RTX.

Director at RTX Ventures, the corporate venture capital arm of RTX.

President and Managing Director at RTX Ventures, the corporate venture capital arm of RTX.

VP, Global Sales Consulting, Trintech. 15 years in sales consulting and digital transformation for government and firms including Stripe, Uber, and Peloton. Wharton EMBA.

Founder & CEO, Carrack Capital. Founder & CEO of Carrack Capital, building liquid, diversified portfolios for cash management and long-term wealth. 15+ years in quantitative investment management, previously Head of Public Markets at Drake Capital and a Director at Ziff Brothers Investments, with earlier roles at BlackRock. Wharton MBA; CFA.

Co-Founder & Principal, Salt + Vinegar. Three decades across media, entertainment, brands, and technology, with clients from Hulu and Adidas to Universal Music Group. Now advises family offices and sovereign wealth funds across MENA, and Singularity Capital Advisors on defense and national security. UCLA.

Senior Aerospace & Defense Executive. 25 years across defense, national security, aerospace, and intelligence, directing over $12B in strategic programs. Formerly CIA, ITT, Lockheed Martin, and Accenture Federal Services. Wharton MBA; JM, Scalia Law.

Chief Technology Officer, Crown Consulting. 35-year NASA Ames career concluding as deputy center director; pioneered unmanned traffic management. Ph.D., Stanford.

Founder & First President, UPS Flight Forward. Holder of the first Standard Part-135 air-carrier certificate for drones in U.S. history. 37-year UPS career.

Founder & CEO, Approach Venture. Advises frontier-tech founding teams; background across A&D banking, venture, and defense-tech operating roles. U.S. Naval Academy.

Lieutenant Colonel, U.S. Army. 20 years in Special Operations, aviation, and intelligence. Rated AH-64 / UH-60 pilot, four combat deployments. Wharton MBA; Penn JD.

Co-Founder & CEO (Ret.), Apogee Engineering. Grew Apogee from $1M to $20M in revenue and 750 employees across 36 states, through 8(a) graduation to its 2024 sale. Earlier at Booz Allen, Lockheed Martin, and General Dynamics on Milstar satellite programs.

Founder & President, AeroX. Built NCDOT’s award-winning UAS program and led its FAA Integration Pilot Program. NASA Aeronautics R&T Roundtable appointee.

Founder & Partner, Osprey Capital · Chairman, AeroX. Former President & COO of B/E Aerospace, leading the supplier to a strategic exit to Boeing and Rockwell Collins. MBA, Harvard.

Principal, Stella Maris Strategies. Distinguished Naval Aviator; commanded HSC-85 and later served as Chief of Staff of NASA. Harvard MPP; Wharton MBA.

Chief Executive Officer, Triman Holdings. Defense and aerospace supply-chain and logistics. Former VP Ops at MAG Aerospace; 23-year USAF KC-10 pilot. Wharton MBA.

Major General, U.S. Army (Ret.). 33rd Commander of the Army JFK Special Warfare Center & School; Commanding General, CJTF–Horn of Africa. West Point.

Founder & CEO, growth[period]. Guided 250+ commercial and federal companies through BD and M&A. Former Corporate VP of Homeland Security at Raytheon.

Chairman & CEO (Ret.), Serco Inc.. Led a $1.5B government-services firm of ~8,000. 30+ years across Lockheed Martin Skunk Works, Raytheon, and VT Group.

President & CEO, JANUS Research Group. Former President & CEO of TCOM, the persistent-surveillance aerostat manufacturer. Two decades leading engineering and growth across defense and industrial technology.

Evaluates opportunities across aerospace, defense, and technology. Previously at Lockheed Martin on naval defense systems, specializing in counter-UAS detection and directed energy. FAA Part 107 Remote Pilot; B.S. Aerospace Engineering, Penn State.

Supports investment research, due diligence, and deal evaluation. Previously at Graham Partners in private equity. Licensed pilot and founder of Fly Beyond Boundaries, a nonprofit that has raised $28,000+ for aviation education in Montana.

Oversees fund and transaction legal operations, entity governance, and compliance across the platform.

Drives investment diligence, sector research, and portfolio monitoring across the firm’s focus areas.

As Aero X Ventures’ Head of Platform, Jay Velasco led portfolio engagement, community and events, and LP strategic partnerships. He publicly announced his final day at the firm on October 2, 2026.

Technology strategist with a decade building, funding, and acquiring aerospace technologies. Former Tech Acquisitions & Strategy Advisor at Booz Allen advising USAF procurement; systems engineer at Northrop Grumman and Raytheon.

Co-founder and CIO; previously Portfolio Manager at iGnosis Capital. An operator who ran FAA Part-135, -141, and -145 aviation businesses and led fintech Zingo to a strategic exit. Eight years at Wells Fargo.

Evaluates therapeutics and medical-device investments for the fund. Holds a UCLA neuroscience doctorate focused on microbiome and nervous-system interactions and a neuroscience bachelor’s degree from UT Austin.

Works on the venture fund and strategic projects at Texas Medical Center. Previously led TMC accelerator programs and studied cancer immunotherapy drug delivery during her Rice University bioengineering doctorate.

Oversees the fund’s investment diligence while leading strategy and new ventures at Texas Medical Center. Previously worked at Cart.com, McKinsey and Schlumberger.

Leads the parent organization’s innovation activities. Previously led JLABS at TMC and held research and business development roles at Shire and Johnson & Johnson Innovation.

President and CEO of the parent Texas Medical Center, with previous healthcare leadership roles at Medtronic, MicroPort and Cellnovo. His fund biography explicitly lists a TMC Venture Fund board seat.

Peter Savitscus was head of trading in Tekla’s own2017 manager presentation. It identifies Villanova education and prior Merrill Lynch experience, with responsibility for trading operations and technical research. Current independent Tekla employment is not inferred.

Joshua Mosberg was a Tekla senior analyst in its2017 presentation, with Washington University/Harvard PhD training and prior Clarion Healthcare experience. The manager identified biotechnology and small-cap therapeutics as his research areas. The source does not establish current2026 employment.

Alan Kwan was a Tekla senior analyst in its2017 presentation, with Washington University PhD/MBA training and prior GlaxoSmithKline experience. His published research areas included life-science tools, diagnostics and medical technology. This is a historical manager role.

Amanda Benson was a senior analyst in Tekla’s own2017 presentation, with Dartmouth PhD training and prior R.A. Capital experience. Her published areas included dermatology, women’s health and biotechnology. This supports a dated historical role rather than current2026 employment.

Christian Richard was a senior vice president in Tekla’s own2017 manager presentation. It identifies New York University MBA training, prior Merlin Biomed and Schering-Plough Research Institute experience, and coverage of cardiovascular disease, biosimilars, inflammation and venture/PIPE investments. This is a historical affiliation.

Graham Attipoe, MD and MBA, is named in the Tekla Healthcare Investors March2023 investment research team. The exact dated primary institutional role is retained; no unverified current position, employment start/end day or individual investment is inferred.

Christopher Seitz joined Tekla in2021 as vice president of research. Its2023 fund filing documents earlier Nantahala Capital Management healthcare analyst internship and Excel Venture Management associate experience, followed by an October2023 transition to abrdn as investment director. The historical role does not establish current 2026 Tekla employment.

Jack Liu, PhD and MBA, was named in the investment team analyzing investments for Tekla Healthcare Investors in its March2023 shareholder report. That primary record supports the historical investment role; exact subsequent employer, employment dates and personal investment amounts are not inferred.

Richard Goss joined Tekla in2018 as vice president of research. The2023 fund filing documents prior Leerink Partners large-pharmaceutical/biotechnology equity research and Datamonitor healthcare analysis, and his move to abrdn as investment director inOctober2023. This is a historical manager affiliation, distinct from personal equity allocations.

Christopher Abbott joined Tekla in2016 and served as vice president of research, previously a Leerink Partners equity research vice president. The2017 manager presentation identifies Hamilton College education and healthcare services/information technology research. The2023 filing documents his October2023 transition to abrdn as investment director.

Ashton Wilson joined Tekla in2018 and served as senior vice president. The2023 fund filing identifies prior Goldman Sachs equity-derivative trading and Bank of America Merrill Lynch experience, followed by an October2023 move to abrdn as senior investment director. Exact current employment beyond the reviewed dated disclosures is not inferred.

Timothy Gasperoni joined Tekla in2015 and served as senior vice president of research. The manager’s2017 presentation identifies UCLA/MIT training, CNS, gastrointestinal and specialty pharmaceutical research, and structured deals. The2023 transition filing documents prior Sabby Capital founding/research, Crosswind and Andesite experience and his October2023 move to abrdn. This is a dated career biography, not a current independent Tekla affiliation.

Daniel R. Omstead led Tekla Capital Management and its four healthcare funds. The manager’s 2017 presentation identifies him as president and CEO with Columbia University training. The 2023 filings identify him as the investment decision maker and document transition to abrdn Inc. His announced successor Jason Akus took over the lead portfolio manager role in June2024, with Omstead’s advisory transition envisaged through September2024; this is not a claim of current 2026 Tekla employment.

Henry Skinner is the Chief Executive Officer of the AMR Action Fund, with a background in microbiology, drug-development investing and pharmaceutical business development. His current own biography confirms prior leadership at Tekla Capital Management and Novartis Venture Fund and CEO roles at SelectX and NeoGenesis Pharmaceuticals. He earned a microbiology PhD and biochemistry MS at the University of Illinois, with additional bioethics/health-law training. Arkuda’s archived2021 company biography names him as a board member and then Tekla Senior Vice President of Venture; the Arkuda affiliation and Tekla title are historical, not assertions of current employment.

Stephanie McTighe was publicly named by Arkuda Therapeutics as Director, Pharmacology. She developed pharmacological models and quantitative studies of candidate compounds with the biology team. Her prior role was head of in-vivo pharmacology at Sage Therapeutics. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Shawna Henry was publicly named by Arkuda Therapeutics as Scientist I. The published company roster establishes this specific role; additional education and employment history are not disclosed in that biography. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Joanna Bryce was named Chief Financial Officer of Arkuda Therapeutics by company co-founder/investor Bruce Booth in November2019, providing financial support to the progranulin/lysosomal drug-discovery company. This is a dated historical appointment; continued Arkuda employment after2019 is unverified.

Serena Hung was publicly named by Arkuda Therapeutics as Chief Medical Officer. She is a neurologist with movement-disorder training and experience in clinical development. Atalanta Therapeutics appointed her Chief Medical Officer May22,2024 and explicitly describes Arkuda as a former employer. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Raymond Hurst was publicly named by Arkuda Therapeutics as Senior Vice President, Discovery. He became Senior Vice President of Discovery in April2023 after serving as Arkuda VP of Pharmacology since2020. His background includes Concert Pharmaceuticals and more than20years in CNS drug discovery. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Mike Esposito was publicly named by Arkuda Therapeutics as Vice President, Finance. The published company roster establishes this specific role; additional education and employment history are not disclosed in that biography. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Irena Webster was publicly named by Arkuda Therapeutics as Vice President, Program Strategy & Dev Ops. She joined Arkuda in April2023 with about two decades of global drug-development experience, including Forma Therapeutics, Sage Therapeutics and Alkermes, and clinical operations across CNS and other therapeutic areas. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Duane Burnett was publicly named by Arkuda Therapeutics as Co-Founder and Chief Technology Officer. He co-founded Arkuda in2018 and became Chief Technology Officer in April2023 after leading discovery. His background includes CNS and cardiovascular medicinal chemistry at Schering-Plough, Merck and FORUM Pharmaceuticals; he contributed to the invention of ezetimibe. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Betsy Kassler was publicly named by Arkuda Therapeutics as Senior Director, Human Resources. The published company roster establishes this specific role; additional education and employment history are not disclosed in that biography. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Xiaowen Peng was publicly named by Arkuda Therapeutics as Director, Medicinal Chemistry. The published company roster establishes this specific role; additional education and employment history are not disclosed in that biography. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Veronika Heil was publicly named by Arkuda Therapeutics as Associate Scientist. The published company roster establishes this specific role; additional education and employment history are not disclosed in that biography. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Richard Gallegos was publicly named by Arkuda Therapeutics as Principal Scientist, DMPK. The published company roster establishes this specific role; additional education and employment history are not disclosed in that biography. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Morgan Brand was publicly named by Arkuda Therapeutics as Associate Scientist. She profiled candidate compounds with chemistry and pharmacology colleagues and contributed to target-identification work. Her background includes Celgene and a chemistry/biology degree from Roger Williams University. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Mary Wozniak was publicly named by Arkuda Therapeutics as Senior Research Associate. She investigated how reduced progranulin affects FTD-GRN. Her biography identifies a behavioral-neuroscience degree from Northeastern University and industry neurodegeneration research experience. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Katie Watters was publicly named by Arkuda Therapeutics as Scientist I. The published company roster establishes this specific role; additional education and employment history are not disclosed in that biography. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

John Ross was publicly named by Arkuda Therapeutics as Associate Director, Toxicology. He directed nonclinical safety work for drug-discovery programmes after experience managing toxicology and safety-pharmacology studies at a CRO. He holds an MS in toxicology and safety pharmacology from Wright State University. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Jim Lanter was publicly named by Arkuda Therapeutics as Vice President, Medicinal Chemistry. He collaborated with external medicinal-chemistry groups across two continents and brought more than two decades of synthetic chemistry experience across therapeutic modalities. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Jean-François Blain was publicly named by Arkuda Therapeutics as Vice President, Neurobiology. He led exploratory biology investigating progranulin and neurodegenerative disease. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Ingrid Ochoa was publicly named by Arkuda Therapeutics as Lab/Facility Manager. The published company roster establishes this specific role; additional education and employment history are not disclosed in that biography. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Hillary Van Voorhies was publicly named by Arkuda Therapeutics as Director, Program Management. She coordinated programmes moving from research into development. Her experience included Alkermes and FORUM Pharmaceuticals and an MS from UMass Amherst. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Giuseppe Astarita was publicly named by Arkuda Therapeutics as Senior Director, Biomarker Dx. The published company roster establishes this specific role; additional education and employment history are not disclosed in that biography. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Gennifer Greenberg was publicly named by Arkuda Therapeutics as Senior Research Associate. The published company roster establishes this specific role; additional education and employment history are not disclosed in that biography. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Denise Peters was publicly named by Arkuda Therapeutics as Accounting Controller. She managed accounting and financial operations after nearly two decades working with medical-device, life-science and biopharma companies. She studied accounting at Nashville State Community College. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Deliwe Jalbert was publicly named by Arkuda Therapeutics as Executive Assistant. The published company roster establishes this specific role; additional education and employment history are not disclosed in that biography. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Christopher Holler was publicly named by Arkuda Therapeutics as Principal Scientist. He helped develop assays for progranulin expression and function in the FTD-GRN discovery programme. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Bonne Thompson was publicly named by Arkuda Therapeutics as Scientist II, Mass Spectrometry. The published company roster establishes this specific role; additional education and employment history are not disclosed in that biography. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Anna-Maria Alves was publicly named by Arkuda Therapeutics as Associate Scientist. She developed progranulin assays and evaluated potential therapies. Her background includes Sanofi-Genzyme and Navitor Pharmaceuticals and an MS in cellular and molecular biology from UMass Amherst. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Angela Chen was publicly named by Arkuda Therapeutics as Scientist II. Her work included biological screening, compound inventories and coordination of outsourced PK/PD studies and animal colonies. Her biography describes over a decade of neurodegeneration research experience. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Robert Urban was publicly named by Arkuda Therapeutics as Independent Board Member. He is a former Johnson & Johnson Innovation global leader, retiring from that role in2018 after an international healthcare career. His Arkuda board seat was independent, not proof of a personal investment or institutional funding allocation. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Ash Khanna is Chief Business Officer of Tentarix Biotherapeutics, appointed in September2025, following a partner role at Pivotal bioVenture Partners. His career includes co-founding Vaxcyte and leading its business development and financing activities, venture investing at SV Health Investors and scientific work at Bristol Myers Squibb. He has a pharmacology PhD from SUNY Buffalo and a Wharton MBA and contributed to the invention of saxagliptin/Onglyza. Arkuda’s archived2023 company roster names him as a board member with a contemporaneous Pivotal title; that affiliation is historical and does not establish current Arkuda board membership or a personal investment.

Denis Patrick is published by Pfizer Ventures as Managing Partner (2025 published roster; current directory omission qualified). Pfizer’s own2025year-in-review namesDenisPatrick asManagingPartner. The live2026twelve-person directory omits him; exact ongoingtenure ordepartureday is not independentlyestablished. The separate issuerMissionTherapeutics published biography describes oncology research atMerck,DuPontPharma andGSK,biochemistry educationatSUNY/UniversityofPennsylvania andbiologyMSatUCSD. These are careerfacts, notpersonal checks or currentoutsidecompanyboardappointments.

Sophia Wood is published by Pfizer Ventures as Executive Assistant. Sophia Wood is the Executive Assistant for the Pfizer Ventures team. Sophia joined the team in 2018 and serves as the core administrative partner managing complex schedules, coordinating high-stakes meetings, and ensuring seamless operations that drives team efficiency. Prior to joining Pfizer, Sophia held various administrative roles at companies including Mount Sinai School of Medicine, NYU Langone Medical Center, St. Vincent’s Medical Center, and Memorial Sloan-Kettering Cancer Center.

Ama Amoah is published by Pfizer Ventures as Finance Director, Business Development. Ama Amoah is the Finance Director, Business Development and serves as the business finance leader on equity investments decisions, partnering with the Pfizer Ventures and Pfizer Breakthrough Growth Initiative teams. She also serves as the primary finance point of contact for business development deals, providing financial leadership on external development opportunities and offering business consultation and analytical support throughout all stages of the BD process. Most recently, Ama provided financial leadership, business consultation, thought partnership and analytical support to the Pfizer Ignite business. She also managed central deals investment decisions within the Pfizer Research and Development Discovery and Early Development organization. Ama rejoined Pfizer in 2019 and supported the I&I RU, Investor Relations, and various teams in the legacy Global Product Development and Worldwide Safety organizations. Previously, she worked for Royal Dutch Shell in Norway, where she performed valuation analyses for JV assets, and led negotiations for long-term gas contracts. Ama holds a BSc in Chemistry from McMaster University and received her MBA from Simmons Graduate School of Management.

Boyoon Choi is published by Pfizer Ventures as Senior Corporate Counsel. Boyoon Choi is Senior Corporate Counsel at Pfizer. Since joining Pfizer in 2021, Boyoon has served as co-counsel to Pfizer Ventures, providing transactional and general legal advice in connection with its equity investing and portfolio management activities. Boyoon has advised on numerous equity and debt financings of both private and public companies as well as strategic fund investments by Pfizer. Boyoon also represents Pfizer in connection with M&A transactions, divestitures and licenses, including most recently the acquisition of Seagen. Prior to joining Pfizer, Boyoon was legal counsel for a global diversified pharmaceutical company, including its corporate venture arm, and an asset manager with over $900 billion in assets under management. Boyoon holds a J.D. from Columbia University (Harlan Fiske Stone Scholar) and a B.A. from Barnard College (summa cum laude) and is admitted to practice law in New York.

Andrew J. Muratore is published by Pfizer Ventures as Vice President & Chief Counsel, M&A and Licensing. Andrew J. Muratore is Vice President and Chief Counsel, M&A and Licensing at Pfizer. Since joining Pfizer in 2008, Andrew has served as lead counsel to Pfizer Ventures and in that role provides transactional and business counselling in support of all aspects of Pfizer’s equity investing activity. Andrew has advised on the evaluation, structuring and execution of numerous public and private equity and debt financings and exit transactions. Andrew also advises the Pfizer Ventures team on securities, compliance, governance and general legal matters. Andrew is Pfizer Venture’s designated board observer to Prescriber Point, Inc. and has previously served on the boards of Neuronetics (NASDAQ: STIM) and G-Con Manufacturing. In addition to support for Pfizer Ventures, Andrew has led many of Pfizer's most significant M&A efforts, including the acquisitions of Metsera, Global Blood Therapeutics, Biohaven, Trillium, Medivation and Hospira, as well as the combination of Pfizer’s consumer healthcare business with GSK’s to create Haleon PLC, the initial public offering and subsequent split-off of Zoetis, Pfizer’s Animal Health business, and the sale of Capsugel to KKR. Andrew joined Pfizer in 2008 from Covington & Burling LLP. He holds a J.D. from New York University (magna cum laude, Order of the Coif) and a B.A. from Colgate University (magna cum laude). Andrew is admitted to practice law in New York.

Cristian Simms is published by Pfizer Ventures as Breakthrough Fellow WWBD, Associate Pfizer Ventures. Cristian Simms is a member of the Pfizer Breakthrough Fellowship Program and currently serves as a Business Development Associate at Pfizer Ventures. He works closely with the Pfizer Ventures team to assess investment opportunities in innovative biotechnology companies and emerging healthcare technologies, while also supporting portfolio management activities across the firm's investment portfolio. Prior to joining Pfizer, Cristian was a Health Policy Fellow at the League of United Latin American Citizens (LULAC). During his fellowship, he authored policy briefs and analyses covering pharmacy benefit manager (PBM) transparency reform, CMS Innovation Center models, 340B reform, and pharmaceutical supply chain legislation. Cristian earned his B.A. from Howard University.

Hila Ravid is identified as PorTal Access’s Vice President of Quality Assurance and Regulatory Affairs in the FDA’s June 2026 FLEXI-PORT clearance letter. She is the named company contact for the K260916 vascular-access port submission.

David Snow joined PorTal Access’s board in February 2026 after four decades of pharmaceutical and biotechnology commercial leadership. He led Regeneron’s commercial immunology team until retirement in 2025 and previously served as President of AstraZeneca China. He holds a business-administration degree from Auburn University and an MBA from NYU Stern.

Angela Dotson leads operations and business development for PorTal Access. Her responsibilities in the issuer’s June 2026 announcement include the commercial strategy, provider and health-system engagement, distributors and strategic partners following FLEXI-PORT clearance. Earlier releases name her Executive Vice President of Business Development and Head of U.S. Operations.

Michael Tal founded PorTal Access and leads its development and commercialisation of implantable vascular-access technology. In the issuer’s June 2026 announcement he describes the company’s goal of improving chemotherapy port placement for patients and clinicians.

Bess Weatherman serves on Avestria’s Fund I limited-partner advisory committee. Her published career includes healthcare investing at Warburg Pincus, leadership of its healthcare group and numerous medical-company directorships. She studied at Mount Holyoke and Stanford Graduate School of Business.

Sharon Fay serves on Avestria’s limited-partner advisory committees for Funds I and II. Her published biography describes a long investment career at AllianceBernstein and international equity portfolio-management experience. She studied at Brown and Harvard Business School.

Bart Epker serves on Avestria’s limited-partner advisory committees for Funds I and II. His published background includes founding-partner and healthcare investment work at PAR Capital Management and earlier experience at TA Associates.

Elisa Zhang is a scientific adviser to Avestria with molecular and cellular biology expertise. Her published research focuses on placental development and disease; she studied at Harvard, completed doctoral work at UC Berkeley and subsequently researched at Stanford.

Karol Watson is an Avestria adviser and cardiologist whose published biography describes UCLA academic work and leadership of its Barbra Streisand Women’s Heart Health Program. Her research spans cardiovascular prevention, hypertension and women’s heart health.